Literature DB >> 17960347

Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling.

David Nichols1, James Chmiel, Melvin Berger.   

Abstract

A vicious cycle of airway obstruction, infection, and inflammation continues to cause most of the morbidity and mortality in cystic fibrosis (CF). Mutations that result in decreased expression or function of the membrane Cl(-) channel, cystic fibrosis transmembrane regulator (CFTR), result in a decrease in the volume (and hence the depth) of liquid on the airway surface, impaired ciliary function, and dehydrated glandular secretions. In turn, these abnormalities contribute to a milieu, which promotes chronic infection with a limited but unique spectrum of microorganisms. Defects in CFTR also perturb regulation of several intracellular signaling pathways including signal transducers and activator of transcription, I-kappaB and nuclear factor-kappa B, and low molecular weight GTPases. Together, these abnormalities result in excessive production of NF-kappaB dependent cytokines such as interleukin (IL)-1, tumor necrosis factor (TNF), IL-6, and IL-8. There are decreased responses to interferon gamma and transforming growth factor beta leading to decreased production of iNOS and NO. Abnormalities of lipid mediators and decreased secretion of counter/regulatory cytokines have also been reported. Together, these effects combine to create a chronic inflammatory process, which damages and obstructs the airways, and eventually claims the life of the patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17960347     DOI: 10.1007/s12016-007-8039-9

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  162 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells.

Authors:  Olivier Tabary; Emilie Boncoeur; Rainer de Martin; Rainer Pepperkok; Annick Clément; Carsten Schultz; Jacky Jacquot
Journal:  Cell Signal       Date:  2005-08-09       Impact factor: 4.315

Review 3.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 4.  Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.

Authors:  Michael W Konstan; Pamela B Davis
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

5.  Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model.

Authors:  B E Barton; J Shortall; J V Jackson
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.

Authors:  Mario Ollero; Omer Junaidi; Munir M Zaman; Iphigenia Tzameli; Adolfo A Ferrando; Charlotte Andersson; Paola G Blanco; Eldad Bialecki; Steven D Freedman
Journal:  J Cell Physiol       Date:  2004-08       Impact factor: 6.384

7.  Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis.

Authors:  Anthony J Kettle; Timothy Chan; Iris Osberg; Revathy Senthilmohan; Anna L P Chapman; Tessa J Mocatta; Jeffrey S Wagener
Journal:  Am J Respir Crit Care Med       Date:  2004-10-01       Impact factor: 21.405

8.  Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.

Authors:  Sonja J Phaff; Harm A W M Tiddens; Henry A Verbrugh; Alewijn Ott
Journal:  J Antimicrob Chemother       Date:  2006-02-09       Impact factor: 5.790

9.  Oxidative changes of bronchoalveolar proteins in cystic fibrosis.

Authors:  Vitaliy Starosta; Ernst Rietschel; Karl Paul; Ulrich Baumann; Matthias Griese
Journal:  Chest       Date:  2006-02       Impact factor: 9.410

10.  Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model.

Authors:  S E Gabriel; K N Brigman; B H Koller; R C Boucher; M J Stutts
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

View more
  49 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression in cystic fibrosis airways: role in oxidant-mediated cell death.

Authors:  Shama Ahmad; Aftab Ahmad; Elena S Dremina; Victor S Sharov; Xiaoling Guo; Tara N Jones; Joan E Loader; Jason R Tatreau; Anne-Laure Perraud; Christian Schöneich; Scott H Randell; Carl W White
Journal:  Am J Respir Crit Care Med       Date:  2009-02-06       Impact factor: 21.405

4.  Anchored PDE4 regulates chloride conductance in wild-type and ΔF508-CFTR human airway epithelia.

Authors:  Elise Blanchard; Lorna Zlock; Anna Lao; Delphine Mika; Wan Namkung; Moses Xie; Colleen Scheitrum; Dieter C Gruenert; Alan S Verkman; Walter E Finkbeiner; Marco Conti; Wito Richter
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

5.  Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Authors:  Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

7.  Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium.

Authors:  Nathan S Alexander; Neal Hatch; Shaoyan Zhang; Daniel Skinner; James Fortenberry; Eric J Sorscher; Bradford A Woodworth
Journal:  Laryngoscope       Date:  2011-04-07       Impact factor: 3.325

8.  Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Cynthia Mattingly; Jessica M Breslow-Deckman; David J Feola
Journal:  J Antimicrob Chemother       Date:  2012-12-17       Impact factor: 5.790

9.  Progress in cystic fibrosis and the CF Therapeutics Development Network.

Authors:  Steven M Rowe; Drucy S Borowitz; Jane L Burns; John P Clancy; Scott H Donaldson; George Retsch-Bogart; Scott D Sagel; Bonnie W Ramsey
Journal:  Thorax       Date:  2012-10       Impact factor: 9.139

10.  AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells.

Authors:  Michael M Myerburg; J Darwin King; Nicholas M Oyster; Adam C Fitch; Amy Magill; Catherine J Baty; Simon C Watkins; Jay K Kolls; Joseph M Pilewski; Kenneth R Hallows
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-17       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.